With a solid cash position and expected profitability by late 2026, Apellis stock is set for recovery. Read the latest ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...